They found mutations primarily in KRAS, TP53, HRAS, and EGFR in thymic carcinomas, while thymomas had mutations in PIK3 CA (6.1%), HRAS (3.03%), and AKT1 (3.03%) genes [23]. This evidence concerns the gene HRAS and thymic carcinoma.